Acton Pharmaceuticals Picks Up Sanofi Drug
Acton Pharmaceuticals, a Marlborough-based drug development firm, has purchased the rights to bring to market a nasal allergy therapy developed by Sanofi U.S.
The company has the right to bring to market Nasacort HFA, a nasal aerosol product Sanofi originally developed to treat allergies.
Sanofi received U.S. Food & Drug Administration approval for the drug, but did not commercially launch it due to technical reasons related to manufacturing scale up.
Acton Pharmaceuticals now has rights to the drug and plans to launch it in the market. Sanofi will still have rights to a similar product, Nasacort AQ, a liquid-based version of the drug.
Correction: An earlier version of this story mischaracterized the U.S. Food & Drug Administration's approval of the Nasacort drug.
WBJ Web Partners
Most Recent
Most Recent
0 Comments